Selective targeted delivery of TNFalpha to tumor blood vessels.
about
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting propertiesWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesThe development of immunoconjugates for targeted cancer therapyOptimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccinesImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteNovel ubiquitin-derived high affinity binding proteins with tumor targeting properties.Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Heptameric targeting ligands against EGFR and HER2 with high stability and avidity.A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapiesUse of the uteroglobin platform for the expression of a bivalent antibody against oncofetal fibronectin in Escherichia coli.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Development trends for generation of single-chain antibody fragments.TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakageAntibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritisTumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.ED-B fibronectin as a target for antibody-based cancer treatments.Antibody-based antiangiogenic cancer therapy.Fibronectin as target for tumor therapy.Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor siteGene therapy targeting to tumor endothelium.New approaches in metastatic melanoma: biological and molecular targeted therapies.The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabineMesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells.Stromal Modulators of TGF-β in Cancer.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.Immunocytokines: a review of molecules in clinical development for cancer therapy.
P2860
Q24320137-83D68E7D-A67F-4506-A3D4-00BFD7DAB35CQ26991991-1DBAE9C2-7D04-461D-B3E8-65456BD920FEQ27021990-EF0C06D8-BD6D-4FB6-B4EF-394A8EE715FEQ27030560-7D93A50F-E0C3-498C-BB27-5EDE4A05D7ADQ28066935-FD956FB1-8D3D-4DF9-AC7E-717963E12B57Q30317537-DD93D916-125A-456D-8B14-CBACB618FBDEQ33325343-72669701-4B6A-4BA8-AE78-B9734C2D8670Q33531787-76E39E87-B004-4085-9376-B14F5736F6F4Q33605532-083DB967-D919-43FF-B7B8-983390494282Q33607479-98A9906D-840D-4B32-9F96-3AE572F997C5Q34253705-14C690CC-6AF2-4107-B300-40B6E9B18954Q34389242-4488D1B3-4F41-4AEE-B1DF-AC79D093CAC0Q34746019-712E79C3-D8C1-4199-B82F-7A2D8D93AA2BQ34756337-AF1B03E8-6D3A-4580-8F98-863ED4F30753Q35075470-27655C0B-ED97-4209-A15E-D3FC822CF500Q35163167-6B2AA832-CAF2-4931-845F-7132BAAAF116Q35216785-5CD79178-0416-4AAE-891E-342C7D25F12BQ35642213-C281BA0A-E413-470E-81E8-5B0DCCC4B489Q35769069-9BBEEE8F-2FDB-42C0-BA45-4BA1D5123878Q35974293-1FFCD80C-185A-4D35-AE60-77B65E13C832Q36123270-93137EC8-0D87-44F5-8AAB-747DA059ED5BQ36158702-4626C748-43DC-461F-B11A-D884B81795B2Q36318555-F3EB7C59-92C7-454D-B505-0EA8FDF651FAQ36354769-45350AEE-5F2A-4534-8C5C-A55B946EC0D6Q36411863-169684CC-EE7B-4EFA-B6BF-8E420FC5CD0EQ36649681-5F94A3E7-7E4D-497F-91F3-9223F4EFAB23Q36817127-B94E6745-4C96-4CA6-BA47-85914EFBE769Q37185752-9DCA17DE-75D4-4130-8E76-ED1B5D2342CDQ37220415-9991E30C-37DE-4A1F-BECF-B97EF2604FB4Q37236248-284A2CAE-B29B-4EF1-9034-82D7546D83E3Q37294534-7922471C-1A83-4702-AC96-EBAC694D5693Q37330712-4B9EEC75-7322-43FB-9FA6-B31065B75698Q37446755-FDC841D6-AE1E-4A4C-ADA0-0A05EFB865BAQ37453905-A19930E8-E2E1-494D-8C39-29E0B986115DQ37485709-4C9A8C6F-C07F-49FD-95CF-CC25E4E692D8Q37566991-1275A2E8-380D-4EE5-A4FA-FE1CBC6C3A94Q37628179-E03D041C-B509-4A75-96A1-50E16DEADB63Q37815128-562D787A-A2CA-4B89-BAF9-90B98D1530DFQ38066025-210C9983-6FF0-4A64-AEF2-FCB842724AFCQ38132742-2E931ADA-A14F-4462-B4D8-E4FF4E6D443C
P2860
Selective targeted delivery of TNFalpha to tumor blood vessels.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Selective targeted delivery of TNFalpha to tumor blood vessels.
@en
Selective targeted delivery of TNFalpha to tumor blood vessels.
@nl
type
label
Selective targeted delivery of TNFalpha to tumor blood vessels.
@en
Selective targeted delivery of TNFalpha to tumor blood vessels.
@nl
prefLabel
Selective targeted delivery of TNFalpha to tumor blood vessels.
@en
Selective targeted delivery of TNFalpha to tumor blood vessels.
@nl
P2093
P1433
P1476
Selective targeted delivery of TNFalpha to tumor blood vessels
@en
P2093
Alexander Berndt
Annalisa Siri
Attila Biro
Barbara Carnemolla
Dario Neri
Enrica Balza
Francesca Sassi
Hartwig Kosmehl
Jessica Grassi
Laura Borsi
P304
P356
10.1182/BLOOD-2003-04-1039
P407
P577
2003-08-21T00:00:00Z